Pharma 3.0: meeting the challenge

Pharma 3.0 is rapidly taking shape. This new health ecosystem promises improved health outcomes for patients, new partnerships with non-traditional players and economic benefits for health care systems. To create the new business models that will redefine the industry, a new customer-focused strategy is needed.

Join Carolyn Buck Luce, Ernst & Young's Global Life Sciences Market Leader, and a panel of industry leaders as they discuss the emerging transformational strategies and key questions, such as:

  • What do life sciences companies need to do to adapt their strategies for success in 3.0?
  • What are the skills and organizational capabilities needed to participate in disruptive new business models?
  • How do you go about implementing the changes that will be needed?
  • What can life sciences companies learn from other industries?

More in Biotechnology & Pharmaceutical

The third place: health care everywhere

2012 Jun 28 10:00 AM Eastern time

 

 

 

 

 

View all in Biotechnology & Pharmaceutical

image

Originally broadcast on:
Tuesday, September 20, 2011
11:00 am Eastern time

(n/a
n/a your local time)

Tue 20 Sep 2011 03:00:00 PM GMT

Duration: 01:02

This is a video webcast. Audio will play through your computer speakers. Video and slides will appear on your screen.

Note: the webcast technology is not compatible with the browser you are using. Use Internet Explorer or Firefox.

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.